Reviva Pharmaceuticals Presented Foundational Preclinical Data on Novel…
<!-- Name:DistributionId Value:8829282 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:True -->…
Browsing Tag
Brilaroxazine
Reviva Pharmaceuticals to Present on Novel Serotonin-Dopamine Stabilizer…
<!-- Name:DistributionId Value:8812521 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Reviva Pharmaceuticals Announces Update on RECOVER, a Pivotal Phase 3 Global Study…
CUPERTINO, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing…
Reviva Pharmaceuticals Announces First Patients Dosed in Pivotal Phase 3 Study and…
- RECOVER is a Phase 3, randomized, double-blind study with registrational intent - - Reviva anticipates expanding the clinical development of brilaroxazine into other neuropsychiatric…